Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

Estelamari Rodriguez, MD, MPH, is breaking down barriers to care by creating Spanish-language content about lung cancer for patients and caregivers.

Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Chinmay Jani, MD, discusses findings from a study evaluating the impact of tobacco use and air pollution on mortality rates in patients with lung cancer.

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.

Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.

According to a study published in Blood Neoplasia, standard-of-care treatment for acute myeloid leukemia is safe and effective for adults over 80.

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine announced the formation of the Sylvester Brain Tumor Institute.

Brandon Mahal, MD, of Sylvester Comprehensive Cancer Center, was commissioned to write a collaborative article on prostate cancer for The Lancet.

Two new grants from the U.S. Department of Defense will support Sylvester Comprehensive Cancer Center studies of endometrial cancer in Black women.

A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.

Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.

Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.

Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Jay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.

Sylvester Comprehensive Cancer Center and NANETS will present a regional educational conference focusing on neuroendocrine tumors.

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.

Jay Spiegel, MD, discusses advancing cellular therapies and challenges in gynecologic cancer treatment.

Some head and neck cancers may respond to the drug olaparib or the combination of olaparib with decitabine.

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia and related blood cancers are often prescribed targeted drugs called BTK inhibitors.

The blood cancer expert comes to Sylvester Comprehensive Cancer Center after leading the discovery and testing of several immunotherapy approaches.